Taking On Challenges And Growing? – Seres Therapeutics Inc (MCRB)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.23 and fluctuated between $1.2550 as its day high and $1.1900 as its day low. The current market capitalization of Seres Therapeutics Inc is $158.99M. A total of 3.53 million shares were traded on the day, compared to an average of 5.34M shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, MCRB has seen 8 BUY and 8 SELL insider trades, representing the acquisition of 113,056 and the disposition of 34,769 shares. Over the last 12 months, there were 10 BUYs and 9 SELLs from insiders. Insiders purchased 175,556 shares during that period but sold 41,807.

In the most recent transaction, Shaff Eric D. sold 8,552 shares of MCRB for 1.35 per share on Oct 30. After the transaction, the CEO and President now owns 115,620 company shares. In a previous transaction on Oct 30, von Moltke Lisa sold 4,232 shares at 1.35 per share. MCRB shares that the insider owns now total 9,513.

Among the insiders who sold shares, DesRosier Thomas disposed of 4,156 shares on Oct 30 at a per-share price of $1.35. This resulted in the Chief Legal Officer and EVP holding 113,891 shares of MCRB after the transaction. In another insider transaction, Arkowitz David sold 4,066 shares at $1.35 per share on Oct 30. Company shares held by the Chief Financial Officer now total 175,756.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for MCRB in the last 3 months, the mean price target is $9.05 with high estimates of $15.00 and low estimates of $1.25. In terms of 52-week highs and lows, MCRB has a high of $6.87 and a low of $0.91.

As of this writing, MCRB has an earnings estimate of $Vanguard Core Bond ETF per share for the current quarter. EPS was calculated based on a consensus of Seres Therapeutics, Inc. estimates, with a high estimate of $Metropolitan Bank Holding Corp. per share and a lower estimate of $Monarch Casino & Resort, Inc.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. MCRB’s latest balance sheet shows that the firm has $290.71M in Cash & Short Term Investments as of fiscal 2021. There were $49.21M in debt and $82.26M in liabilities at the time. Its Book Value Per Share was -$0.12, while its Total Shareholder’s Equity was $131.51M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MCRB is Buy with a score of 4.67.